Thalidomide possesses antiangiogenesis properties via the suppression of the vascular endothelial growth factor,[15] which has been shown to be strongly expressed in GIVM.[16] Thalidomide also possesses immunomodulating, antitumor, and antiinflammatory properties, but its nefarious teratogenic effects may limit its use.[15,17,18] Thalidomide was successfully used for the treatment of recurrent gastric bleeding in a patient with hereditary hemorrhagic telangiectasia (HHT)[19] and for the treatment of cirrhotic patients with severe anemia secondary to vascular malformation.[20]. This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.